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ARTICLE
CRISPR activation screen in mice identifies novel
membrane proteins enhancing pulmonary
metastatic colonisation
Louise van der Weyden 1, Victoria Harle1,7, Gemma Turner1,7, Victoria Offord1, Vivek Iyer1, Alastair Droop 1,
Agnieszka Swiatkowska1, Roy Rabbie 1, Andrew D. Campbell 2, Owen J. Sansom 2,3, Mercedes Pardo 4,
Jyoti S. Choudhary 4, Ingrid Ferreira 1, Mark Tullett5, Mark J. Arends 6, Anneliese O. Speak 1 &
David J. Adams 1✉
Melanoma represents ~5% of all cutaneous malignancies, yet accounts for the majority of
skin cancer deaths due to its propensity to metastasise. To develop new therapies, novel
target molecules must to be identified and the accessibility of cell surface proteins makes
them attractive targets. Using CRISPR activation technology, we screened a library of guide
RNAs targeting membrane protein-encoding genes to identify cell surface molecules whose
upregulation enhances the metastatic pulmonary colonisation capabilities of tumour cells
in vivo. We show that upregulated expression of the cell surface protein LRRN4CL led to
increased pulmonary metastases in mice. Critically, LRRN4CL expression was elevated in
melanoma patient samples, with high expression levels correlating with decreased survival.
Collectively, our findings uncover an unappreciated role for LRRN4CL in the outcome of
melanoma patients and identifies a potential therapeutic target and biomarker.
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Metastasis is the spread of cancer cells to a secondary siteand is the leading cause of death in cancer patients.Metastatic dissemination of a tumour is a multi-step
process and involves tumour cell invasion of the lymphatics and/
or blood vessels, survival in the circulation and extravasation at a
distant site. Following this, the disseminated tumour cells (DTCs)
must proliferate and colonise the secondary site to become an
overt, clinically relevant metastasis. In vivo video-microscopy has
shown that the early steps of the metastatic process are relatively
efficient, and it is the regulation of DTC growth at the secondary
site that determines metastatic outcome1. Thus, colonisation is a
critical and rate-limiting step in the formation of clinically rele-
vant metastases. The lungs are common sites of metastasis across
many different cancer types, in part due to the fact that blood and
lymphatic fluids returning from the periphery are pumped by the
heart through the pulmonary microvasculature. More than 80%
of metastatic melanoma patients initially show the involvement of
only one distant organ site, which is most commonly the lungs2.
Thus, controlling metastatic colonisation in the lungs is of critical
importance for patient management.
The importance of cell surface proteins in the metastatic process
is well-established, as they play critical roles in both signalling and
adhesion interactions between tumour cells and the micro-
environment. For example, there are cell-surface proteins that are
functionally linked to tumour cell intravasation3 and others that
specifically induce homing to the lung microvasculature4. Cell
surface proteins are also attractive drug and immunological targets
due to their accessibility such as the transmembrane oncoprotein
HER2 (encoded by ERBB2), which is overexpressed in ~20% of
invasive breast cancers and can be specifically targeted with the
humanised IgG1 antibody, Trastuzumab (Herceptin®)5. More
recently, a study used quantitative surface proteomics to reveal
proteins upregulated on human cancer cells transformed with
KRASG12V, and found that antibodies targeting the CUB domain-
containing protein 1 (CDCP1), a single-pass transmembrane
protein highly overexpressed in a diverse range of human cancers,
could be used to deliver cytotoxic and immunotherapeutic pay-
loads to RAS-transformed cancer cells in vivo6,7. Indeed, whilst
cell surface molecules represent only ~22% of all proteins encoded
in the human genome, many approved drugs target over-
expressed/mutated cell surface molecules (or their natural ligands)
to suppress aberrant signalling pathways8,9.
Traditionally, mass-spectrometry-based proteomics has been
used to identify cell surface proteins important for cancer and
metastasis3,6. In this study, we applied CRISPR activation
(CRISPRa) technology to screen a membrane protein guide RNA
(gRNA) library using an experimental metastasis assay with
melanoma cells in mice. This screen identified cell surface pro-
teins whose upregulated expression in melanoma cells resulted in
enhanced pulmonary metastatic colonisation, and thus represent
potential therapeutic targets and biomarkers.
Results
Screening and identification of LRRN4CL. To identify cell-
surface proteins whose upregulation results in the enhanced ability
of melanoma cells to colonise the lung, we performed an experi-
mental metastasis assay in mice using the weakly metastatic B16-F0
mouse melanoma cell line. B16-F0 cells expressing dCas9 (B16-F0-
dCas9) were virally transduced with a CRISPRa gRNA library
targeting genes that encode membrane proteins (‘m6’ library;
Fig. 1a). The library contained 11,225 gRNAs in total, and was
composed of gRNAs targeting 2195 membrane protein-encoding
genes (with five guides/gene) and 250 non-targeting ‘control’
gRNAs, cloned into the pCRISPRia_v2 vector backbone10. Wild-
type mice (n= 70) were tail vein dosed with 5.5 × 105 cells
(representing a 50× coverage of the library), then randomised into
two cohorts: 35 mice were collected after 4 h (to assess the ability of
gRNA-carrying tumour cells to enter the lung) and 35 mice were
collected at 19 days (when the mice started showing clinical signs of
pulmonary tumour burden). Genomic DNA (gDNA) was extracted
from the lungs of the mice (after saline perfusion) and high-
throughput sequencing of the gRNAs performed to identify their
representation at 4 h and 19 days, relative to that present in the
transduced B16-F0-dCas9 cell population before injection (Sup-
plementary Fig. 1a). While the gRNA representation present in the
pre-injection cells was comparable with that in the plasmid library
(considering all gene-targeting and non-targeting control gRNAs),
the gRNA representation in the 4-h and 19-day lung samples was
significantly decreased, with anyone mouse carrying only ~20% of
the gRNAs present in the library (Supplementary Fig. 1b), sug-
gesting that extravasation and subsequent survival in the lung was a
major biological bottleneck. In addition, the 19-day lung samples
had enrichment of a subset of gRNAs, suggesting positive selection
for cells carrying these gRNAs during the growth of the metastases
(Supplementary Fig. 1c). To identify gRNAs significantly enriched
in these mice, we considered two approaches: the ‘percentile
ranking’ (PR) approach, which was based on single gRNA abun-
dance amongst multiple mice (gRNAs found in the top 98th per-
centile of abundance/mouse), and a ‘JACKS’ analysis11, which
considered the relative abundance of all five gRNAs for each gene
amongst tumours collected from multiple mice. Using the PR
approach, the top two genes (gRNAs) were Lrrn4cl and Slc4a3
(Supplementary Table 1); using JACKS analysis, the top two genes
were Lrrn4cl and Tm4sf19 (Supplementary Table 2). An experi-
mental metastasis assay was performed using B16-F0-dCas9 mela-
noma cells transduced with single gRNAs targeting each of these
three genes separately. Targeting of each gene resulted in a sig-
nificant enhancement of the ability of the cells to colonise the lung,
relative to cells transduced with a pool of three non-targeting
control gRNAs (Fig. 1b).
Given that Lrrn4cl (Leucine-Rich Repeat Neuronal 4 C-Terminal
Like) was identified as a ‘hit’ in both analyses, and showed the
strongest enhancement of pulmonary metastatic capabilities, we
chose to further characterise this gene. Consistent with the
phenotype observed when B16-F0 cells were virally transduced
with the dCas9/CRISPRa system to upregulate Lrrn4cl expression,
transfection of a Lrrn4cl cDNA-containing plasmid into B16-F0
cells also resulted in enhanced pulmonary metastatic colonisation
(Fig. 1c, d). Mouse and human Lrrn4cl/LRRN4CL are two-exon
genes (with the entire coding region contained in exon 2) that
encode 239 and 238 amino acid proteins, respectively, which show
66% identity (Fig. 1e). LRRN4CL is predicted by UniProtKB to be
a single-pass type I integral membrane protein with a signal
peptide, large ECD, small transmembrane/helical domain and a
short cytoplasmic tail (Fig. 1e). The extracellular portion of the
protein is predicted to undergo N-linked glycosylation (at position
N132 in human and at N132 and N174 in mouse) and contains a
fibronectin type-III (FN3) domain, found in many proteins
involved in ligand binding (Fig. 1e). PNGase F-digestion of B16-
F0 cell lysates expressing a FLAG/streptavidin-tagged Lrrn4cl
cDNA (LRRN4CL-FSA) caused a shift of the LRRN4CL-FSA band
to a lower molecular weight, confirming that LRRN4CL is
glycosylated (Supplementary Fig. 2a). Images of anti-LRRN4CL
immunohistochemical staining of human tissues showed that in
the tonsil there was a strong expression on the cell membranes (in
a ring pattern) and in the colon, there was mostly cell membrane
staining (with enhanced staining at the luminal surface of
colonocytes) and some cytoplasmic staining (Supplementary
Fig. 2b, c). Tissue expression of LRRN4CL from the NCBI
BioProject database (human data from PRJEB433712) showed
only low levels of expression in normal tissues (the highest
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expression is in the endometrium and ovary, with a mean of 5.9
RPKM for each) (Supplementary Fig. 2d), in agreement with
proteomic data from the Human Proteome Map. We next
generated and phenotyped Lrrn4cl knockout mice, finding them to
be homozygous viable and fertile, in agreement with other
studies13 and displaying no gross differences compared with
wildtype control mice in body weight, soft tissue mass, lean mass,
fat mass, bone mineral content or bone mineral density
(Supplementary Fig. 2e). Both of these factors are critical for
LRRN4CL to be considered as a therapeutic target.
Upregulated LRRN4CL expression confers enhanced lung-
specific metastatic colonisation. To confirm that the observed
phenotype was not specific to B16-F0 melanoma cells, we
expressed Lrrn4cl cDNA in three other mouse melanoma cell lines
(HCmel12, YUMM1.7 and B16-BL6 cells [the latter of which
already displays a high metastatic propensity]) and observed
increased pulmonary metastatic colonisation relative to cells
transfected with the empty vector alone (Fig. 2a). To assess
whether the phenotype associated with Lrrn4cl upregulation was
specific to melanoma cells, we expressed the Lrrn4cl cDNA in
Fig. 1 Performing a CRISPRa screen in vivo to identify cell surface regulators of pulmonary metastatic colonisation. a Graphic representation of the
screen outline. b The number of metastatic colonies in the lungs of mice 10 days after being tail vein dosed with 2 × 105 B16-F0-dCas9 cells carrying gRNAs
against the genes listed. NTC, non-targeting control. c The number of metastatic colonies in the lungs of mice 10 days after being tail vein dosed with 1 ×
105 B16-F0 cells that have been stably transfected with a plasmid carrying the Lrrn4cl cDNA (LRN) or an empty vector (PB). d The number of metastatic
colonies in the lungs of mice 10 days after being tail vein dosed with 4 × 105 B16-F0 cells that have been stably transfected with a vector carrying the Lrrn4cl
cDNA (LRN) or an empty vector (PB). For (b-d), each symbol represents a mouse, the bars represent mean ± SD, 2 independent experiments performed
(representative data from one experiment is shown) and statistics performed using a Mann–Whitney t test. e The human and mouse LRRN4CL protein
sequences (ENSP00000325808 and ENSMUSP00000093976, respectively) were aligned CLUSTAL W (1.81) in Ensembl. Below each site amino acid of
the alignment is a key denoting conserved sites (*), sites with conservative replacements (:), sites with semi-conservative replacements (.), and sites with
non-conservative replacements (). The UniProtKB predicted location of the signal peptide (orange), extracellular domain (blue), transmembrane domain
(red), cytoplasmic domain (green), FN3 domain (underlined) and N-linked glycosylation site at N132 (arrow) for human LRRN4CL are shown
(glycosylation sites for the mouse also shown: arrows at N132 and N174).
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three non-melanoma mouse cancer cell lines (MC-38 colorectal
cancer cells, MB-47 bladder cancer cells and EO771 breast cancer
cells) and the same effect was observed (Fig. 2b). Furthermore, we
performed an additional screen using tail vein dosed E0771-dCas9
cells transduced with the membrane protein (m6) CRISPRa gRNA
library and collected the lungs of the mice when they showed signs
of pulmonary tumour burden. Using the PR approach to identify
gRNAs significantly enriched in these mice, we found the top hit
in this screen was a gRNA targeting Lrrn4cl (the same one found
in the B16-F0 screen; Lrrn4cl_+_8850757.23-P1P2). Indeed, all
five gRNAs targeting Lrrn4cl were found in the 98th percentile of
at least one mouse in this screen. Thus, although we identified
Lrrn4cl in melanoma cells, it mediates pulmonary colonisation cell
lines from other tumour types.
We next expressed the human LRRN4CL cDNA in two human
melanoma cell lines, A375 and MeWo (Western blot confirming
upregulated expression shown in Supplementary Fig. 3) and again
observed increased pulmonary metastatic colonisation relative to
cells transfected with the empty vector alone (Fig. 2c). Similarly,
expression of human LRRN4CL cDNA in mouse B16-F0 cells
resulted in increased pulmonary metastatic colonisation (Fig. 2c),
suggesting a conserved role in the regulation of metastatic
colonisation.
Tail vein dosing of mouse HCmel12 melanoma cells primarily
resulted in pulmonary metastases, however, extrapulmonary
metastases were also observed in some mice, specifically within
the liver (that was not observed with other cell lines). It was
interesting to note that the expression of Lrrn4cl cDNA did not
result in increased hepatic metastatic colonisation (Fig. 2d).
Similarly, when mouse B16-F0 melanoma cells were tail vein
dosed into immunodeficient (NOD-SCID) mice, in addition to
pulmonary metastases, hepatic metastases were also noted, and
expression of Lrrn4cl cDNA resulted in the cells showing
significantly decreased hepatic metastatic colonisation (Fig. 2d).
Intrasplenic injection of B16-F0 cells, which results in hepatic
metastatic colonisation, showed no difference in the number of
hepatic metastatic colonies between Lrrn4cl over-expressing cells
and control cells (Fig. 2d). These data suggest that it is specifically
pulmonary metastatic colonisation that is enhanced by Lrrn4cl
and not metastatic colonisation in general.
Fig. 2 The effect of LRRN4CL over-expression on metastatic colonisation. a The number of metastatic colonies in the lungs of mice 10 days after being
tail vein dosed with melanoma cell lines (5 × 105 HCmel12 cells, 4 × 105 YUMM1.7 cells and 0.25 × 105 B16-BL6 cells) that have been stably transfected
with a vector carrying mouse Lrrn4cl cDNA (LRN) or an empty vector (PB). b The number of metastatic colonies in the lungs of mice 10 days after being tail
vein dosed with a colorectal cell line (4 × 105 MC-38 cells), bladder cancer cell line (4 × 105 MB-49 cells), or breast cancer cell line (4 × 105 EO771 cells)
that have been stably transfected with a vector carrying mouse Lrrn4cl cDNA (LRN) or an empty vector (PB). c The number of metastatic colonies in the
lungs of mice 30 days after being tail vein dosed with human melanoma cell lines (2 × 105 A375 cells or 0.5 × 105 MeWo cells) or 10 days after being dosed
with a mouse melanoma cell line (4 × 105 B16-F0 cells) that have been stably transfected a vector carrying human LRRN4CL cDNA (LRN) or an empty
vector (PB). For a–c, each symbol represents a mouse, the bars represent mean ± SD, two independent experiments were performed (representative data
from one experiment is shown) and statistics were performed using a Mann–Whitney t test. d The number of metastatic colonies in the livers of mice after
being tail vein dosed (with 5 × 105 HCmel12 cells (wild-type mice) or 1 × 105 B16-F0 cells (NOD-SCID mice)) or intrasplenic dosed (0.1 × 105 B16-F0 cells
(wildtype mice)) with melanoma cells that have been stably transfected a vector carrying mouse Lrrn4cl cDNA (LRN) or an empty vector (PB). Each
symbol represents a mouse, the bars represent mean ± SD, and statistics were performed using a Mann–Whitney t test.
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Insight into the mechanism of action of LRRN4CL-mediated
pulmonary colonisation. To understand the mechanism of
action of Lrrn4cl, we tail vein injected wildtype mice with fluor-
escently labelled B16-F0 cells (transfected with Lrrn4cl cDNA
[F0_LRN] or empty vector backbone [F0_PB]). After 1 or 3 h, the
lungs were flushed with saline to remove any blood and tumour
cells from the blood vessels, and we assessed the number of
tumour cells that had undergone extravasation into the lungs. As
shown in Fig. 3a, there was no difference in the number of
F0_LRN or F0_PB tumour cells present in the saline-rinsed lungs
at either 1 or 3 h post dosing. This suggests that expression of the
Lrrn4cl cDNA did not enhance the ability of the tumour cells to
extravasate. To ascertain whether LRRN4CL expression aided
evasion of NK, T and B cells, B16-F0 cells were tail vein dosed
into immunocompromised (NOD-SCID) mice and, similar to
results in the wildtype mice, F0_LRN cells had significantly
increased pulmonary metastatic colonisation relative to F0_PB
cells (Fig. 3b). This suggests that the Lrrn4cl-mediated phenotype
was not primarily regulated by NK, T and B cells. Furthermore,
Lrrn4cl expression did not affect the primary tumour growth of
B16-F0 melanoma cells subcutaneously administered to wildtype
mice (Fig. 3c).
LRRN4CL is a novel gene whose function has not yet been
characterised, so we first sought to identify protein binding
partners. Using cell microarray screening technology, we assessed
the ability of the extracellular domain (ECD) of human LRRN4CL
(amino acids 23-194, C-terminally Fc tagged) to bind to members
of a cDNA library encoding >5500 full-length human plasma
membrane and tethered secreted proteins, expressed on the cell
surface of human HEK293 cells. We identified a positive interaction
between the human LRRN4CL ECD (LRRN4CL_ECD) and
CRTAC1 (human CRTAC1α, human CRTAC1β and mouse
CRTAC1), and validated this using a flow cytometric assay
(Supplementary Fig. 4a, b). Positive interactions were also observed
between LRRN4CL_ECD and various members of the Fc gamma
receptor family, however, these were expected interactions mediated
by the Fc domains of the test Fc fusion protein and/or the detection
antibody. Although CRTAC1 is strongly expressed in the human
lung, Crtac1 is barely detectable in the mouse lung (Supplementary
Fig. 4c–e). These data are in agreement with a recently published
study that shows the evolutionary divergence of lung cell types and
expression patterns between mouse and human, with CRTAC1
being an example of a gene that is expressed by human AT2 cells
but not by mouse AT2 cells14. Tail vein dosing of F0_LRN cells in
Crtac1 null mice resulted in no difference in the number of
pulmonary metastatic colonies compared with wildtype mice
(Supplementary Fig. 4f). This suggests that, at least in mice,
LRRN4CL does not mediate the enhanced metastatic pulmonary
colonisation phenotype through binding to CRTAC1.
We next applied in vitro assays to examine whether LRRN4CL
affected the following intrinsic properties of melanoma cells that
are generally associated with increased metastatic potential: general
growth rate in vitro, invasion and migration, epithelial–
mesenchymal transition, matrix metalloprotease (MMP) produc-
tion, and self-renewal. Upregulated expression of LRRN4CL in
A375 cells had no effect on any of these characteristics
(Supplementary Fig. 5), which suggested that either LRRN4CL
promotes lung metastasis by mechanisms distinct from the
aforementioned processes, or that LRRN4CL only mediated its
effects when in the lung microenvironment.
Based on these data, we considered a potential role for
LRRN4CL in the later stages of the metastatic process, specifically
DTC survival and subsequent outgrowth in the lung parenchyma.
As an upregulated expression of LRRN4CL only produced a
phenotype in the in vivo context, we performed RNA-seq on
A375 melanoma cells that were tail vein dosed and grown in the
lungs of mice for 21 days, in addition to cells grown in vitro, to
identify any differentially expressed genes between these two
contexts. Principal component analysis (PCA) grouped the
samples into four clusters (Supplementary Fig. 6a): control cells
grown in vitro (VITRO_E), LRRN4CL over-expressing cells
grown in vitro (VITRO_L), control cells from the mouse lung
(VIVO_E) and LRRN4CL over-expressing cells from the mouse
lung (VIVO_L). Two samples, ‘VIVO_L1c’ and ‘VIVO_L3a’,
were outliers from the VIVO_L group and so were excluded from
the analysis. Interestingly the expression of LRRN4CL in the
control cells was increased in vivo, relative to in vitro (VITRO_E
cells versus VIVO_E cells; Supplementary Fig. 6b). Using a log2
fold change cut-off of (1, −1) and an adjusted P value of P < 0.01,
there were 115 significantly differentially expressed genes (DEGs;
Fig. 3 Investigation of the mechanism of action of LRRN4CL. a The number of CFDA-positive B16-F0 cells present in the lung (per 2 million lung cells
counted) after either 1- or 3-h post-tail vein dosing. The cells were stably transfected with a vector carrying mouse Lrrn4cl cDNA (LRN) or an empty vector
(PB), and then labelled with the fluorescent tracker dye, CFDA. Each symbol represents a mouse, the bars represent mean ± SD, and statistics were
performed using a Mann–Whitney t test. b The number of metastatic colonies in the lungs of either wildtype or immunodeficient (NOD-SCID) mice 10 days
after being tail vein dosed with B16-F0 cells that have been stably transfected with a vector carrying mouse Lrrn4cl cDNA (LRN) or an empty vector (PB).
Each symbol represents a mouse, the bars represent mean ± SD, two independent experiments were performed (representative data from one experiment
is shown) and statistics were performed using a Mann–Whitney t test. c The growth of B16-F0 cells that have been stably transfected with a vector
carrying mouse Lrrn4cl cDNA (LRN) or an empty vector (PB) after subcutaneous administration into the flank of wildtype mice. The data are shown as
mean ± SEM with n= 8–9 mice per cell line per experiment. Two independent experiments were performed (representative data from one experiment is
shown).
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including nine non-protein-coding genes) between LRRN4CL
over-expressing (A375_LRN) cells and control (A375_E) cells
that were only found in the in vivo context (Supplementary
Data 1). There were 75 down-regulated genes and 40 upregulated
genes, grouped into eight clusters (Supplementary Fig. 7). Gene
set enrichment analysis (GSEA), using two different programmes
found the most statistically significantly downregulated pathways
to be ‘interferon signalling’ (Padj= 0.0002; Reactome) and
‘interferon alpha’ and ‘interferon gamma’ (Padj= 5.5 × 10−5;
Hallmark) (Supplementary Fig. 8a, b). The genes in these
pathways were in clusters 6 and 7, which showed the most
striking differences between the control cells and LRRN4CL over-
expressing cells in vivo (Fig. 4). Using the 13 genes from the
Reactome ‘interferon signalling’ pathway as a ‘signature’ in
survival analysis, decreased expression of these genes correlated
with worse survival of melanoma patients (TCGA cohort;
Supplementary Fig. 8c). Of the DEGs that were significantly
up-regulated, many have known roles in promoting metastasis,
including LOXL1, MMP28, HAS1 and FPR1. Thus, in the lung,
the enhanced expression of LRRN4CL allows the cells to enter a
pro-metastatic phenotype.
LRRN4CL is highly expressed in melanoma and correlates with
worse patient survival. The TCGA database shows there is a
range of LRRN4CL mRNA expression levels across 32 cancer
types; expression is enriched in melanomas, with cutaneous
melanoma and uveal melanoma showing the highest levels
(Fig. 5a). Using the TCGA dataset, higher expression levels of
LRRN4CL (top 25% quartile) significantly correlated with a
poorer outcome (disease-specific survival) in cancer patients in
general (all cancer types included in the analysis; Cox Log-rank
P= 2.2 × 10−16, age- and sex-adjusted; Fig. 5b). In melanoma
patients, high expression of LRRN4CL significantly correlated
with worse outcome, in both the TCGA dataset (Cox Log-rank
P= 0.0008, age- and sex-adjusted; Fig. 5c), and the AVAST-M
dataset15 (Cox Log-rank P= 0.048 [univariate analyses], Fig. 5d
and Supplementary Fig. 9a, respectively). Interestingly, in uveal
melanoma patients, higher expression of LRRN4CL did not cor-
relate with clinical outcome (Supplementary Fig. 9b). Whilst this
could possibly be due to the limited number of patients in this
cohort (n= 20), it is important to note that uveal melanoma
shows a strong preference for metastasis to the liver16 (where we
showed upregulated expression of LRRN4CL did not result in
enhanced metastatic colonisation abilities; Fig. 2d). Analysis of
the TCGA datasets also showed that high expression of LRRN4CL
correlated with worse outcome in low-grade glioma, renal clear
cell carcinoma and ovarian carcinoma (univariate analysis, Log-
rank P= 1.17 × 10−6, 0.027 and 0.048, respectively; Supplemen-
tary Fig. 9c–e).
Discussion
To identify cell-surface proteins whose upregulation results in an
enhanced ability of melanoma cells to colonise the lung, we
performed an in vivo CRISPRa screen in mice using B16-F0
mouse melanoma cells transduced with a library of ‘membrane
protein’ CRISPRa gRNAs (Fig. 1a). We used an experimental
metastasis assay that focuses on later stages of the metastatic
cascade, specifically tumour cell extravasation, and survival and
subsequent proliferation at the secondary site to become overt
metastases17. We chose to use B16-F0 cells for the initial screen as
we and others have previously shown that they are very weakly
metastatic18 and thus would lead to less ‘background’ in the
screen, i.e., cells that will enter the lung and proliferate, regardless
of the gRNA they are carrying, due to their inherent ability to
metastasise. Analysis of the lungs at 4 h post dosing with tumour
cells revealed that only ~20% of the total number of gRNAs were
present in any one mouse, although the whole library was
represented across the cohort of 35 mice (Supplementary Fig. 1).
Such a strong biological bottleneck is consistent with previous
reports of tail vein administration of the related weakly metastatic
B16-F1 melanoma cells, in which only ~64% of the cells were
present in the lung 2 min post dosing, and only ~32% after 3 h19.
The CRISPRa system has been successfully used in vivo for
screening pools of gRNAs targeting transcription start sites of 1–2
genes20,21, however, as yet there have been no large-scale in vivo
screens performed using this system. Thus, we utilised two dif-
ferent approaches by which to identify genes (gRNAs) enriched in
the lungs of mice at 19 days post dosing. The first method, similar
to that used in a recent genome-scale in vivo Cas9/CRISPR screen
in T cells22, was to rank the individual gRNAs based on their
relative abundance within each mouse (at the 19-day time point)
and identify those in the top 98th percentile. In this analysis, the
majority of enriched gRNAs were present in ≤2 mice, however,
two gRNAs were identified in 4 mice and 3 mice, which targeted
Lrrn4cl and Slc4a3, respectively. Lrrn4cl encodes a protein of
unknown function and Slc4a3 (solute carrier family 4 members 3)
encodes a plasma membrane anion exchange chloride/bicarbo-
nate transporter (also known as AE3) that has been shown to be
involved in cellular transformation, with upregulated expression
affecting cell viability and cellular attachment23. The second
method was to use ‘JACKS’ (Joint Analysis of CRISPR/Cas9
Knockout Screens)11 which is a Bayesian method that models
variable gRNA efficacies and thus considers all five gRNAs per
gene during hit identification. Using this analysis, ranking the
output by the mean of the JACKS score at 19 days minus the
mean of the JACKS score at 4 h, the top two genes were Lrrn4cl
and Tm4sf19. Tm4sf19 (transmembrane 4L six family member 19,
also known as Octm4) is a member of the four-transmembrane
L6 superfamily, which includes TM4SF1, whose overexpression in
many cancers is associated with poor prognosis, and has roles in
proliferation, invasion, and metastasis24. However, little is cur-
rently known about TM4SF19, although it was recently shown
that lipopolysaccharides could upregulate TM4SF19 expression,
resulting in reduced VE-cadherin expression and weakened
endothelial cell adherens junctions25. Given that LRRN4CL was
the top ‘hit’ of both analyses, we focused our efforts on this gene.
LRRN4CL is predicted to be a single-pass type I transmem-
brane protein. We have shown here that upregulated expression
of mouse and human LRRN4CL resulted in an enhanced ability
of metastatic tumour cells (both melanoma and other cell types)
to colonise the lungs in mice (Figs. 1 and 2a–c). This phenotype
was not due to an increased ability to extravasate from the cir-
culation to the lung (Fig. 3a), nor an ability to avoid NK cells,
T cells and B cells (Fig. 3b). The enhanced metastatic colonisation
abilities of LRRN4CL appeared lung-specific, as the only extra-
pulmonary metastases observed were in the liver and LRRN4CL
over-expression did not increase hepatic colonisation (Fig. 2d).
We did not observe any phenotypic differences compared with
wildtype cells in terms of in vitro metastatic capabilities (Sup-
plementary Fig. 5). In addition, upregulated expression of
LRRN4CL in melanoma cells did not result in any phenotypic
difference, compared with control cells, in primary tumour
growth in the skin after subcutaneous administration into the
flank (Fig. 3c).
As upregulated LRRN4CL expression only provided an advan-
tage to metastatic tumour cells in the lung, with no phenotypic
effect observed in vitro, we performed RNAseq of human A375
melanoma cells expressing LRRN4CL (A375_LRNmCherry cells;
‘L’) that had been colonising the lung for 21 days. We looked
for differentially expressed genes, relative to control cells
(A375_EVmCherry cells; ‘E’) after removing any genes that were
ARTICLE COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-021-01912-w
6 COMMUNICATIONS BIOLOGY |           (2021) 4:395 | https://doi.org/10.1038/s42003-021-01912-w | www.nature.com/commsbio
differentially expressed genes in vitro. A heatmap of the differ-
entially expressed genes and GSEA using both Reactome and
Hallmark datasets showed that the most significantly down-
regulated genes belonged to pathways involved in ‘interferon
(IFN) signalling’ and interferon-alpha response’/‘interferon-
gamma response’, with decreased expression of genes in these
pathways correlating with worse survival in melanoma patients
(Fig. 4 and Supplementary Figs. 7 and 8). Interestingly, IFNs have
been demonstrated to counteract melanoma development through
both cell-autonomous and non-cell-autonomous mechanisms, and
IFN signalling is even more critical for suppressing metastatic
melanoma spread26. A375_LRNmCherry cells also had strong
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in vivo upregulation of many genes with a known role in pro-
moting metastasis. Examples include LOXL1 (lysyl oxidase-like 1),
with poorer survival of patients that have LOXL1-positive gastric
cancer due to distant metastasis27; MMP28 (matrix metallopepti-
dase 28), which is a promoter of invasion and metastasis in gastric
cancer28; HAS1 (hyaluronan synthase 1), which has been shown to
play a role in the metastasis of breast cancer cells29; and FPR1
(formyl peptide receptor 1), which is a cell-surface receptor
expressed by highly malignant human glioma cells that mediates
metastasis by regulating motility, growth, and angiogenesis
through interactions with host-derived agonists30. Thus, upregu-
lated LRRN4CL expression promoted lung-specific metastasis that
was associated with microenvironment-stimulated cell-intrinsic
downregulation of IFN signalling and upregulation of pro-
metastatic pathways. Interestingly, LRRN4CL is upregulated in
glioma cells that express high levels of MDA9, which plays an
important role in cancer progression, particularly during the
invasion/metastasis stage31,32. The highest expression of
LRRN4CL in the TCGA dataset was observed in cutaneous and
uveal melanoma, both of which have a propensity to metastasise
(Fig. 5a). Critically, high expression of LRRN4CL was significantly
correlated with worse outcome in cancer patients, across all can-
cers represented in TCGA (Fig. 5b). High expression of LRRN4CL
also correlated with poorer disease-specific survival in cutaneous
melanoma patients (as assessed across two independent datasets;
Fig. 5b, c), as well as for other cancer types (Supplementary Fig. 9).
Fig. 4 In vitro and in vivo differentially expressed genes between A375 melanoma cells expressing LRRN4CL or empty vector. Cluster 6 and 7 of the
heatmap of the differentially expressed genes (DEGs) between A375 melanoma cells over-expressing LRRN4CL (L) and A375 cells transduced with the
empty vector (E) that were growing in vitro (VITRO) or in the lungs of mice for 21 days (VIVO). Supplementary Figure 7 shows the full heatmap with all
eight clusters. Three independent experiments were performed (cohorts 1–3) with four samples (a–d) per experiment per cell line (two samples are not
shown on the heatmap as they were outliers on the PCA). Genes were scored as differentially expressed if they had a log2 fold change≤−1 or ≥+1 with a
Padj < 0.01. Individual genes within gene set enrichment analysis (GSEA)-identified significantly down-regulated pathways are shown
(‘interferon_signaling’, ‘interferon_gamma’, ‘interferon_alpha’).
Fig. 5 LRRN4CL expression in tumours and its correlation to patient outcome. a LRRN4CL expression (RSEM) amongst different tumour types (data from
TCGA). Bar represents the median, box represents the interquartile range. Whiskers represent 1.5 * IQR. Abbreviations: HCC hepatocellular carcinoma,
THCA well-differentiated thyroid cancer, LEUK leukaemia, SEM seminoma, RNCCC renal non-clear cell carcinoma, BMCN mature B-cell neoplasms, TET
thymic epithelial tumour, CHOL cholangiosarcoma, NSCLC non-small cell lung cancer, HNSCC head and neck squamous cell carcinoma, RCCC renal clear
cell carcinoma, CSCC cervical squamous cell carcinoma, OSCC oesophageal squamous cell carcinoma, NCGCT non-seminomatous germ cell tumour,
BRCA invasive breast carcinoma, GBMLGG diffuse glioma, UC bladder urothelial carcinoma, COADCA colorectal adenocarcinoma, CEAD cervical
adenocarcinoma, PCC pheochromocytoma, OSCA oesophagogastric neuroepithelial tumour, MNET miscellaneous neuroepithelial tumour, OET ovarian
epithelial tumour, ACC adrenocortical carcinoma, UCEC endometrial carcinoma, MESO pleural mesothelioma, PRAD prostate adenocarcinoma, PAAD
pancreatic adenocarcinoma, GBM glioblastoma, SARC sarcoma, SKCM cutaneous melanoma, UM uveal melanoma. b Kaplan–Meier curves for disease-
specific survival across all cancer patients from the TCGA dataset. Expression levels of LRRN4CL as lower 25th percentile (‘low LRRN4CL’) or upper 25th
percentile (‘high LRRN4CL’). Cox Log-rank P value, age- and sex-adjusted. c Kaplan–Meier curves for disease-specific survival in cutaneous melanoma
patients from the TCGA dataset. Expression levels of LRRN4CL as lower 25th percentile (‘low LRRN4CL’) or upper 25th percentile (‘high LRRN4CL’). Cox
Log-rank P value, age- and sex-adjusted. d Kaplan–Meier curves for progression-free survival in cutaneous melanoma patients from the phase III adjuvant
AVAST-M dataset15. Expression levels of LRRN4CL as lower 25th percentile (‘low LRRN4CL’) or upper 25th percentile (‘high LRRN4CL’). Cox Log-rank P
value, univariate analysis. The numbers in brackets on each graph indicate the number of patient samples per group.
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Taken together with previous findings that LRRN4CL is not highly
expressed in normal tissues and Lrrn4cl knockout mice show no
overt phenotypes, we conclude that LRRN4CL represents an
attractive therapeutic candidate for the prevention of metastatic
colonisation.
Methods
Cell lines. The mouse melanoma B16-F0 cell line was purchased from ATCC and
the mouse melanoma B16-BL6 cell line was purchased from the University of
Texas, MD Anderson Cancer Center; both were authenticated by whole genome
and transcriptome sequencing33. The human melanoma A375 and MeWo cell lines
were purchased from ATCC and verified by STR profiling. The other cell lines were
gifts from the laboratories that generated them: the mouse melanoma HCmel12 cell
line was from T. Tuting (University Hospital Magdeburg, Germany)34, the mouse
melanoma YUMM1.7 cell line was from M. Bosenberg (Yale University School of
Medicine, USA)35, the mouse colorectal MC-38 cell line was a gift from L. Borsig
(University of Zurich, Switzerland)36, the mouse mammary cancer EO771.LMB cell
line was a gift from R. L. Anderson (Peter MacCallum Cancer Centre, Australia)37,
and the mouse bladder cancer MB-49 cell line was from A. Hegele (Philipps
University of Marburg, Germany)38. The cell lines were grown in either DMEM
(B16-F0, B16-BL6, HCmel12, YUMM1.7, MC-38, E0771 and A375) or RPMI (MB-
49 and MeWo), with 10% (v/v) foetal calf serum (FCS) and 2 mM glutamine,
100 U/mL penicillin/streptomycin at 37 °C, 5% CO2 (with the addition of 1%
minimum non-essential amino acids for YUMM1.7 cells and 20 mM HEPES for
EO771 cells). The cell lines were screened for the presence of mycoplasma and
mouse pathogens (at Charles River Laboratories, USA) before culturing and never
cultured for more than five passages.
Mice. Wildtype mice were C57BL/6NTac and immunodeficient mice were NOD.
CgPrkdcscid, Il2rgtm1Wjl/SzJ. Both lines were originally obtained from JAX
Laboratories and maintained as core colonies at the Sanger Institute Research
Support Facility. Lrrn4cl ‘knockout’ (Lrrn4clem1(IMPC)Wtsi) mice were generated at
the Welcome Sanger Institute using CRISPR technology to disrupt the coding exon
of Lrrn4cl using published methods39 and phenotyped using an Ultrafocus100
densitometer (Faxitron). Heterozygous Crtac1 (C57BL/6NTac-Crtac1em1(IMPC)H/
H) mice were obtained from the MRC Harwell Institute which distributes these
mice on behalf of the European Mouse Mutant Archive (www.emmanet.org)40 and
re-derived into the Sanger Institute Research Support Facility. The diet, cage
conditions and room conditions of the mice were as previously detailed41. The care
and use of all mice in this study were in accordance with the Home Office
guidelines of the UK and procedures were performed under a UK Home Office
Project License (P6B8058B0), which was reviewed and approved by the Sanger
Institute’s Animal Welfare and Ethical Review Body.
Experimental metastasis assay. The use of the experimental assay as a screen for
pulmonary metastatic colonisation ability has been detailed previously17. For tail
vein injections, the cells were resuspended in 0.1 mL phosphate-buffered saline
(PBS) and injected into the lateral tail vein of 6- to 12-week-old wildtype or
immunodeficient mice (both sexes were used but the mice were always of the same
sex within an experimental cohort). The number of cells administered via the tail
vein was dependent upon the cell line and experiment (detailed in the relevant
figure legend). After 10 days (or 20–30 days for human cell lines) the mice were
humanely sacrificed, their lungs removed and washed in PBS and the number of
metastatic foci determined. As the B16-F0, B16-BL6 and HCmel12 cell lines pro-
duce pigmented metastases, their metastatic burden was determined by micro-
scopic counting of the number of tumour foci on the surface of all five lobes of the
lung by a single individual that was blind to the cell line administered to the mice.
For all other cell lines, the lungs were fixed in 10% neutral-buffered formalin,
paraffin-embedded, sectioned and haematoxylin and eosin (H&E) stained (as per
routine histology techniques). The metastatic burden was determined by counting
the number of tumour foci in one coronal section of all five lobes of lung by a
pathologist that was blind to the cell line administered to the mice. For intrasplenic
injections41, the experiments were performed using wildtype mice and B16-F0 cells
(1 × 104). The metastatic burden was determined by counting the number of
tumour foci in five sections of the liver. For all experimental metastasis assays, the
raw data (number of metastatic foci counted in each mouse dosed with either the
experimental or relevant control cell line) from each cohort of dosed mice was
subjected to the non-parametric Mann–Whitney t test to determine significance.
CRISPR activation membrane protein screen. The mouse membrane protein
(‘m6’) mCRISPRa-v2 subpooled library (consisting of 10,975 gRNAs targeting 2104
genes that encode for membrane proteins, and 250 non-targeting control gRNAs)
was generated by Jonathan Weissman10 and acquired from Addgene (#84003). The
m6 plasmid library was packaged into lentivirus in HEK293T cells and transduced
into a previously established B16-F0 mouse melanoma cell line stably expressing
dCas9 (‘dCas9-F0 cells’; the blasticidin-resistant dCas9 plasmid was a gift from
Gavin Wright42). A total of 12 × 106 dCas9-F0 cells were transduced with the m6
library lentivirus at an MOI of 0.3 with 8 μg/mL polybrene. After 48 h, cells were
passaged (16 × 106 cells re-seeded) and 5 μg/mL of puromycin added to the
medium (flow cytometry was used to measure BFP expression and confirm suc-
cessful transduction). After a further 4 days, cells were passaged again, maintaining
12 × 106 cells. On day 9, cells were detached, counted, centrifuged at 300g for 5 min
then diluted in PBS. Aliquots of 5.5 × 106 and 1.1 × 106 cells (500× and 100× library
representation, respectively) were pelleted and snap-frozen (representing ‘0-h’
timepoint) and aliquots of 5.5 × 105 cells (50× library representation) in 100 μL PBS
were intravenously administered (via tail vein) into 70 wildtype female mice aged
6–8 weeks. At two time points (4 h and 19 days post dosing), the mice were
humanely sacrificed and saline cardiac perfused, with the lungs then being snap-
frozen (labelled ‘Lung_11’ - ‘Lung_45’ for the 4-h cohort and ‘Lung_46’–‘Lung_80’
for 19-day cohort). The lungs from each mouse (all five lobes) were homogenised
in 1 mL Tris-buffered saline with 0.5% Triton X-100 and a portion taken for gDNA
extraction (including 0-h timepoint dCas9-F0 cell pellets) using the Purgene kit
(Qiagen) according to manufacturer’s instructions. PCR reactions were performed
with 500 ng of gDNA per reaction, using the Phusion® High-Fidelity PCR Master
Mix with HF Buffer (NEB) to amplify the gRNAs. The forward primer contained
an 8mer barcode, 5′ Illumina adapters and homology to the CRISPRia-v2
plasmid10. The reverse primer contained 3′ Illumina adapters and homology to the
CRISPRia-v2 plasmid10. For each lung, 16 PCR reactions were performed and
all products were pooled. A portion of this was purified to select for the desired
~280 bp product, using a Select-a-Size DNA Clean & Concentrator kit according to
the manufacturer’s protocol (Zymo). PCR was also performed on duplicate 0-h
dCas9-F0 cell gDNA and the library plasmid DNA. Purity of all PCR samples was
confirmed by analysis on a Bioanalyser. The samples were then combined in two
pools, each containing 41 samples (1 plasmid sample, 2 cell line samples and 38
lung samples) and sequenced over 2 runs on a HiSeq2500 (Illumina). To ensure
consistency between the 2 runs, 6 of the 70 lung samples in total were sequenced
‘twice’ with each duplicate being in a different pool/run to its original sample
(specifically ‘Lung_49b’, ‘Lung_56b’, ‘Lung_58b, ‘Lung_66b’, ‘Lung_73b’ and
‘Lung_75b’). Two sequencing primers were used: a bespoke primer and a standard
Illumina primer.
A screen was also performed using the EO771 mouse breast cancer cell line
stably expressing dCas9 (‘dCas9-EO cells’). The screen was performed as described
above, except that the 70 mice were divided into three independent cohorts (‘A’=
23 mice, ‘B’= 23 mice, ‘C’= 24 mice). Each cohort was tail vein dosed with
independent replicates of 5.5 × 105 library-carrying dCas9-EO cells, and the mice
were collected as and when they showed signs of pulmonary tumour burden, which
was 18–28 days post dosing. In addition, three aliquots of 5.5 × 106 cells (500×
library representation) were pelleted and snap-frozen per library replicate
(representing ‘0-h’ timepoint). The purified PCR products of all 79 samples
(70 lung samples, labelled ‘EOp_A1-A23’, ‘EOp_B1-B23’ and ‘EOp_C1-C24’; 3 sets
of cell line samples in triplicate, labelled ‘EOp_cells_A1, A2, A3’, ‘EOp_cells_B1,
B2, B3’, ‘EOp_cells_C1, C2, C3’) were pooled and sequenced over 1 run of a
HiSeq2500 (Illumina). The analysis was performed using the ‘percentile’ method as
described below, with all three cohorts analysed together.
Bioinformatic analysis of the gRNAs. Single-end reads (50 bp) were trimmed to
remove adapter sequences and compared for exact matches against 11,225 sgRNAs
from the Weissman murine membrane proteins (m6) library (‘Top5’ gRNAs
including 250 non-targeting controls) [https://www.addgene.org/pooled-library/
weissman-mouse-crispra-v2-subpools/]. Guides with fewer than 30 reads in either
of the ‘cell_500×’ replicates were removed from the resulting count matrix. Two
methods were used to identify enriched gRNAs: the ‘percentile’ method and the
‘JACKS’ method. For the ‘percentile’ method, total normalisation was performed
with MAGeCK (version 0.5.8)43, using ‘cells_500×’ samples as the control. gRNAs
with no reads assigned were removed post-normalisation. For each gRNA at 19 d
and 4 h, the count means, standard deviation, a number of samples in which the
gRNA was present (group count) were generated. The standard error of the mean
was calculated for each gRNA at 4 h and 19 d as the standard deviation divided by
the square root of the group count. A per-gRNA z-score at 4 h and 19 d was
determined as the normalised count minus the mean of the control counts, divided
by the group SEM. gRNAs were ranked by z-score for each sample individually and
gRNAs which were present in the 98th percentile in multiple samples identified.
For the ‘JACKS’ method, a Bayesian analysis of the screen was performed using
JACKS11 (version: March 2018). Each sample was treated as an independent
replicate, with all samples at the 4 h time point and all samples at the 19 d time-
point grouped together respectively, while the ‘cells_500×’ samples were used as the
control. JACKS provides a gene-by-gene list of effect sizes and the standard
deviations of the effect sizes for both the 19 d and 4 h samples. The effect of the
gRNA on the metastatic potential of the cells was represented by both the differ-
ence of estimated JACKS effect sizes at 19 d compared to 4 h, and a ‘z-score’ which
represents the difference of effect sizes divided by the standard deviation of the
effect at 19 d.
Validation of CRISPR activation screen ‘hits’. Individual gRNAs were cloned
between the BstXI and BlpI sites of the CRISPRia-v2 plasmid using standard Weissman
Lab protocols as recommended (https://weissmanlab.ucsf.edu/CRISPR/CRISPR.html).
The gRNAs from the m6 library used for validation were ‘Lrrn4cl_+_8850757.23-
P1P2’, ‘Slc4a3_+_75546398.23-P1P2’, ‘Tm4sf19_-_32400563.23-P1P2’ and
COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-021-01912-w ARTICLE
COMMUNICATIONS BIOLOGY |           (2021) 4:395 | https://doi.org/10.1038/s42003-021-01912-w |www.nature.com/commsbio 9
‘non-targeting_01320–01324’. The plasmids were packaged into lentiviruses and
dCas9-F0 cells were transduced and used in the experimental metastasis assay as
detailed above.
Generating Lrrn4cl/LRRN4CL-overexpressing cell lines. For upregulated
expression of LRRN4CL, the mouse or human Lrrn4cl/LRRN4CL cDNA (synthe-
sised by GeneArt) was cloned into the multiple cloning site of the ‘PB-CMV-MCS-
EF1α-Puro PiggyBac’ vector (PB510B-1) or ‘PB-EF1α-MCS-IRES-Neo PiggyBac’
vector (PB533A-2; System Biosciences). The stably-expressing Lrrn4cl/LRRN4CL
cell lines were generated by co-transfection of the cells with 2 µg of either the
Lrrn4cl/LRRN4CL-containing plasmids or 2 µg of the ‘empty’ plasmid, and 0.5 µg
of PBase-expressing plasmid using Fugene HD (Promega) according to the man-
ufacturer’s recommendations. After selection in puromycin or G418 (Invivogen)
for 7–10 days, the resulting colonies for each transfection were pooled to make the
LRRN4CL expressing cell line (‘LRN’) or the control cell line (‘PB’), with the cells
being maintained in puromycin or G418 throughout.
To generated a ‘tagged’ version of LRRN4CL, an in-frame FLAG sequence and
streptavidin sequence (216 bp) was included at the C-terminus of the mouse
Lrrn4cl cDNA prior to the stop codon (synthesised by GeneArt) and cloned into
the multiple cloning site of the PB510B-1 vector and a stably-expressing B16-F0
cell line (termed ‘LRRN4CL-FSA’ cells) generated as detailed above. For
upregulated expression of LRRN4CL in a mCherry-expressing plasmid, human
LRRN4CL cDNA was cloned into the multiple cloning site of the pReceiver-Lv206
plasmid (EX-NEG-Lv206; Genecopoeia). The plasmid was packaged into a
lentivirus and used to transduce the A375 cell line (or the ‘empty vector’ virus was
used to generate a ‘control’ cell line). After 48 h, the cells were placed in 2 µg/mL
puromycin (which was maintained throughout their culturing). After 14 days in
culture, cell sorting was performed (MoFlo XDP, Beckman Coulter) to select for
those cells expressing the highest level of mCherry within the population.
Cell growth assays. Totally, 5 × 104 A375 cells were seeded per well of a 12-well
plate. At 24, 48 and 72 h cells were harvested by trypsinisation and counted using
trypan blue exclusion. The average of four wells was taken per technical replicate
and three independent biological replicates of each cell line performed.
Migration and invasion assays. For migration assays, 24-well transwell chambers
with 8.0 µm PET membranes were used and for invasion assays, Matrigel-coated
invasion chambers with the same specification were used (Corning). A375 cells
were serum-starved overnight before plating 2.5 × 104 cells per chamber in 200 μL
serum-free DMEM medium. Wells were filled with 700 μL DMEM containing 10%
FCS to encourage migration. Cells were incubated for 18 h for migration and 24 h
for invasion assays. Following incubation, migrated cells attached to the reverse
side of the membrane were fixed with methanol for 10 min and stained with
Giemsa stain solution (Sigma). Three images were captured per technical replicate
(in triplicate) using a light microscope with a camera (Leica Application Suite), and
cells were counted manually using ImageJ (with three independent biological
replicates of each cell line carried out).
Glycosylation analysis. Deglycosylation of whole-cell lysates from B16-F0 cells
expressing a FLAG/streptavidin-tagged Lrrn4cl cDNA (LRRN4CL-FSA) was car-
ried out with PNGase F (New England Biolabs) according to the manufacturer’s
instructions.
Western blots. Cells were lysed in RIPA lysis buffer (Merck Millipore) with the
addition of phosphatase inhibitor (Sigma). Protein was quantified using a BCA
assay and 50 μg protein loaded per well. Proteins were separated by SDS-PAGE and
transferred to PVDF membrane. Membranes were blocked in 5% non-fat milk.
Primary antibodies were as follows: Epithelial–Mesenchymal Transition Antibody
Sampler Kit (note: expression of Slug was not detected in A375 cells; 1:1000
dilution, Cell Signalling #9782), Matrix Remodelling Antibody Sampler Kit (1:1000
dilution, Cell Signalling #73959), StemLight™ Pluripotency Transcription Factor
Antibody Kit (note: expression of Nanog and Oct-4A was not detected in A375
cells; 1:1000 dilution, Cell Signalling #9093), LRRN4CL antibody—middle region
(1:1000 dilution, Aviva Systems Biology, #OAAB0898), β-Actin (8H10D10) mouse
monoclonal Antibody (1:2000 dilution, Cell Signalling #3700), α-Tubulin Antibody
(1:1000 dilution, Cell Signalling #2144), and mouse monoclonal anti-FLAG® M2-
Peroxidase (1:5000 dilution, Sigma #A8592). Secondary antibodies were as follows:
anti-mouse IgG HRP-linked antibody (1:10,000, Cell Signalling #7076) and anti-
rabbit IgG HRP-linked antibody (1:10,000, Cell Signalling #7074). The blots were
visualised using chemiluminescence detection by the ImageQuant LAS 4000
machine (GE Healthcare). For all western blots, β-actin or α-tubulin were used as
loading controls and run on the same gel as the corresponding protein of interest
(membrane was either cut into sections for the different antibodies or stripped and
re-probed with the loading control antibody).
Gene expression. RNA was extracted from tissues using an RNeasy fibrous kit
(Qiagen) according to the manufacturer’s instructions. Crtac1 gene expression was
assessed using FAM-conjugated TaqMan assays (Mm00513940_m1). Template
RNA was added in duplex reactions in triplicate with endogenous control B2m VIC
primer limited probe (Mm00437762_m1), using QuantiNova Probe RT-PCR kit
(Qiagen) with an Applied Biosystems Quantstudio 7 Flex Real-Time PCR system
(ThermoFisher Scientific). Relative gene expression between endogenous control
and target genes were analysed using the ΔΔCT method44 with QuantStudio
Software.
Retrogenix cell microarray. Primary and confirmatory screens with 10 μg/mL of a
fusion protein consisting of the ECD of human LRRN4CL (amino acids 23–194)
C-terminally linked to a human Fc domain (LRRN4CL-ECD-Fc; produced by
Absolute Antibody) were carried out as detailed previously45, based on probing an
array of live human HEK293 cells over-expressing 5528 human transmembrane
and cell-surface tethered soluble proteins. The positive control was the interaction
between CD20 (one of the cDNAs within the library) and 1 μg/mL of Rituximab
biosimilar antibody. The negative control was the use of PBS in place of the
LRRN4CL-ECD-Fc. Detection of an interaction was visualised using Alexa-
Fluor647 anti-human IgG Fc. For the flow cytometric validation assay, expression
vectors encoding ZsGreen1 only, or encoding both ZsGreen1 and human
CRTAC1α, human CRTAC1β, mouse Crtac1 or CD20 (positive control), were
transfected, in duplicate, into human HEK293 cells. Live transfectants were incu-
bated with 10 µg/mL LRRN4CL-ECD-Fc or 1 µg/mL Rituximab biosimilar positive
control. Cells were washed and incubated with AF647 anti-human IgG Fc detection
antibody as used in the cell microarray study. Cells were again washed, and ana-
lysed by flow cytometry using an Accuri (Becton Dickinson). A 7AAD live/dead
dye was used to exclude dead cells in the analysis, and ZsGreen+ (transfected) cells
were selected for analysis.
Preparation of lung cell suspensions. Mice were perfused with 20 mL PBS by
cardiac puncture. The perfused lungs were removed and disrupted in C tubes using
the programme ‘m_lung_01’ with a gentleMACS (Miltenyi Biotec) in Hanks
Balanced Salt solution containing calcium and magnesium. Liberase DL (Col-
lagenase with low dispase content, Roche) was added to a final concentration of
0.1 U/mL and incubated for 30 min at 37 °C. The tubes were then processed using
programme ‘m_lung_02’ and DNase (0.1 mg/mL) was added for a further 30 min
at 37 °C. The resulting cell suspension was centrifuged at 400g for 5 min, resus-
pended in 2 mL fluorescence-activated cell sorting (FACS) buffer (D-PBS without
calcium and magnesium-containing 2 mM EDTA, 0.5% FCS and 0.09% sodium
azide), passed through a 30 µm cell strainer and analysed on the flow cytometer. To
determine the number of melanoma cells present in the lungs of mice, the mice
were tail vein dosed with 9 × 105 F0_LRN or F0_PB cells (pre-labelled with 10 µM
CFDA (Molecular Probes, Invitrogen)) at 1 or 3 h before perfusion. An example of
the gating strategy to detect CDFA+ tumour cells in the lung is shown in Sup-
plementary Fig. 10, where an undosed mouse lung and the parental cell lines were
used as negative and positive gating controls, respectively.
Transcriptome sequencing. Immunodeficient mice tail vein dosed with 2.5 × 105
A375_LRNmCherry or A375_EVmCherry cells were humanely sacrificed after
21 days and lung cell suspensions prepared using a human tumour dissociation kit
(Miltenyi Biotec), followed by a mouse-cell depletion kit (Miltenyi Biotec),
according to the manufacturer’s instructions. Using a cell sorter (FACSAria Illu,
Becton-Dickinson), A375_mCherry cells were identified after displaying in a
bivariate plot of SSC-log versus mCherry by gating on high forward scatter versus
side scatter to exclude some debris and dead cells and positively sorted. RNA was
extracted from the sorted cells, as well as A375_LRNmCherry or A375_EVm-
Cherry cells grown in vitro, using the RNeasy Mini kit (Qiagen), according to the
manufacturer’s instructions, and used to generate cDNA with the Smart-seq2
protocol46,47. Multiplexed sequencing libraries were generated from amplified
cDNA using Nextera XT (Illumina). Multiplexed libraries were pooled and
sequenced across multiple lanes on the Illumina HiSeq 2500 (V4). Paired-end
75 bp reads were aligned with STAR version 2.5.0c48. STAR genome index files
were generated using a GTF file corresponding to gene models from Ensembl
version 77 and reference genome version GRCh38. Read counting was performed
with htseq-count from the HTSeq package (0.7.2)49. PCA identified two samples as
outliers which were subsequently removed: VIVO_L1c and VIVO_L3a. Differential
gene expression analysis was conducted with DESeq2 (version 1.26.0)50. After
Benjamini-Hochberg correction, only genes with an adjusted p value of <0.01 and a
log2 fold change ≥ 1 or ≤−1 were considered to be significantly differentially
expressed. Fast GSEA (FGSEA) was performed on 115 genes which were identified
as being unique to the VIVO environment (LRRN4CL over-expression vs. empty
vector) using the R package fgsea (version 1.12.0)51 with the MSigDB (version 7.0)
Hallmark and Reactome gene sets52.
LRRN4CL expression levels in normal tissues, human tumours and survival.
Tissue RPKM expression data were extracted from the NCBI BioProject database
(human data from PRJEB433712 and mouse data from PRJNA6616753). RPKM
values for selected genes per tissue were extracted. Error bars show RPKM ± 1
standard deviation where available. LRRN4CL RSEM54-normalised RNA expres-
sion data for all TCGA PanCancer Atlas Studies were downloaded from the
cBioPortal55,56. These expression data are derived from the TCGA RNASeqV2
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data. Expression data were filtered to remove any cancer types with fewer than
matching 15 samples. The expression data were plotted using a logarithmic scale
with a smooth transition to a linear scale close to zero to show low-expression data
(using pseudo_log from ggplot257). Sample survival data (both overall and disease-
specific) were extracted from the TCGA PanCancer Atlas clinical data. LRRN4CL
RSEM-normalised RNA expression data were extracted. Samples with LRRN4CL
expression values in the top and bottom 25% were selected for analysis. Kaplan-
Meier survival curves were created in R using the survival package (version 3.1-
12)58 for pan-cancer, cutaneous melanoma and uveal melanoma patient data and
using OncoLnc59 for a low-grade glioma, kidney renal clear cell carcinoma and
ovarian carcinoma patient data. Cox Log-rank (Mantel–Cox) test p values were
calculated. For the phase III adjuvant AVAST-M study15, the clinical data acquired
and the extracted RNA from the primary melanomas embedded in this study that
were sequenced on the Illumina exome-capture sequencing platform were as
previously described60. Kaplan–Meier survival curves were generated for the top
and bottom 25% expression values as detailed above. The standardised LRRN4CL
expression scores were then used as a continuous predictor in Cox regression
models fitted by means of the coxph function of the survival package (v2.2-3)
[https://CRAN.R-project.org/package=survival] in R (v3.5.1). The hazard ratio
(95% CI) and p values corresponding to the signature were reported in both
univariate and multivariate analyses. The clinical covariates stage, sex, age, number
of involved regional lymph nodes, Eastern Cooperative Oncology Group perfor-
mance status and treatment were considered in the multivariate survival model.
Overall survival curves using the 13 differentially expressed genes from the RNAseq
experiment that were in the Reactome ‘interferon signalling’ pathway was per-
formed using GEPIA 2 [http://gepia2.cancer-pku.cn/#survival] on the ‘SKCM’
cohort from TCGA and statistics were calculated using the log-rank (Mantel–Cox)
test.
Statistics and reproducibility. Statistical significance was assessed using either the
non-parametric Mann–Whitney t test (for experimental metastasis assays) or the
unpaired two-tailed t test (for in vitro assays). Statistical significance of differential
gene expression in the transcriptomics data was assessed using DESeq2, correcting
for multiple hypothesis testing using the Benjamini–Hochberg adjustment proce-
dure. Statistical testing of the two groups displayed on the Kaplan–Meier survival
curves was performed using the Log-rank test within the Cox’s proportional
hazards model, whilst correcting for clinical covariates as indicated.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The CRISPR data are available under the European Nucleotide Archive (ENA) accession
number ERP123242 and the RNAseq data are available under the European Genome-
phenome Archive (EGA) accession number EGAD00001006249. All source data for the
figures are available in Supplementary Data 2. All relevant data are available from D.J.A.
upon request.
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